ClinicalTrials.gg
CompletedNCT04231136Updated Dec 1, 2020

Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers

A Phase 1 interventional study of Tegoprazan 50 mg and EAPA115 in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-01.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Study summary

This study aims to evaluate the pharmacodynamics after single oral dosing of tegoprazan, EAPA115 and RAPA115 in healthy volunteers.

Read the detailed description

Evaluation Criteria

  • Pharmacodynamic assessments with intragastric pH
  • Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 19 to 65 years (not inclusive) at the time of signing the form (ICF).
  • (BMI) ≥ 17.5 and \< 30.5 kg/m\^2 with a body weight ≥ 45 kg at screening. Body mass index (kg/m\^2) = weight (kg)/height (m)\^2
  • Confirmed as H. pylori negative
  • A subject without any congenital or chronic disease within 3 years, and has no medical examination result as pathological symptoms or signs.
  • A subject determined eligible for this study based on the screening test such as clinical laboratory tests (hematology test, chemistry test, urine test, virus/bacteria test, etc.), vital signs, and .
  • A subject who is fully informed of the purpose and content of the study and agrees to participate in the study on its own will and signs the consent form approved by the Institutional Review Board (IRB) of the Seoul National University Hospital, prior to participate in the study.
  • A subject who has the ability and willingness to participate throughout the whole study period.

Exclusion criteria

Exclusion Criteria:

  • A subject with blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychical, neurologic, or immunologic diseases (except for simple dental past history such as tartar, impacted tooth, or wisdom tooth) or evidence.
  • A subject with a history of gastrointestinal disorders (esophageal diseases such as esophageal achalasia or esophageal stricture, Crohn's disease) or surgery (except for simple appendectomy, herniotomy, and tooth extraction surgery) that may affect the absorption of drugs.
  • A subject with the *17 allele of CYP2C19 (Ultrarapid metabolizer).
  • A subject with and ALT levels exceeding 3 times of the upper limit of the reference range in the screening test.
  • A subject with a history of excessive caffeine (> 5 units/day) or regular alcohol consumption exceeding 210 g/week within 6 months of screening test. (1 glass of beer (5%) (250 mL) = 10 g, 1 shot of soju (20%) (50 mL) = 8 g, 1 glass of wine (12%) (125 mL) = 12 g)
  • A subject who participated in other clinical trial or bioequivalence study and administered the study medication within 6 months prior to the first administration of the product of this study.
  • A subject with significant alcohol or drug abuse within a year of screening test.
  • A subject who administered drugs that significantly induce or inhibit drug metabolizing enzymes within 30 days prior to the first administration of the investigational product of this study.
  • A subject who smoked cigarettes more than 20 per day within 6 months of screening test.
  • A subject who administered prescribed drug or over-the-counter drug within 10 days prior to the first administration of the investigational product of this study.
  • A subject who has donated whole blood within 2 months or those who donated the component blood within 1 month prior to the first administration of the investigational product of this study.
  • A subject who has to the investigational product of this study, benzimidazoles, penicillin and macrolide and its related medical history.
  • A subject with rare genetic problems such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency.
  • Pregnant or nursing women
  • A subject who cannot use reliable during the entire period of the clinical trial (e.g, condom use, intrauterine device, tubal ligation, cervical cap, contraceptive diaphragm, etc.).
  • A subject who is judged by the investigator to be ineligible to participate in the test.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Tegoprazan 50 mg

    Oral administration of Tegoprazan 50 mg tablet once a day

    Drug: Tegoprazan 50 mg

  • Active comparator
    EAPA115

    Oral administration of EAPA115 once a day

    Drug: EAPA115

  • Active comparator
    RAPA115

    Oral administration of RAPA115 once a day

    Drug: RAPA115

Interventions

  • Tegoprazan 50 mg tablet

    Also known as: K-CAB

  • DrugEAPA115

    EAPA115

  • DrugRAPA115

    RAPA115

06

What researchers measure

Primary outcomes

  1. Pharmacodynamic Evaluation

    The ratio of duration(Duration %) with pH ≥ 4 over 24 hours

    Time frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period

  2. Pharmacodynamic Evaluation

    The ratio of duration(Duration %) with pH ≥ 6 over 24 hours

    Time frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period

  3. Pharmacodynamic Evaluation

    Median pH

    Time frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period

  4. Pharmacodynamic Evaluation

    Mean pH

    Time frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period

  5. Pharmacodynamic Evaluation

    Baseline pH and changes in pH after the administration of investigational products (change of duration %, change of mean pH, change of median pH)

    Time frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period

  6. Pharmacodynamic Evaluation

    The ratio of duration(Duration %) with pH ≥ 4 during nocturnal period\* (\*12 hours after administration of investigational product)

    Time frame: Pre-dose(0 hour) up to 12 hours after Investigational product administration in each period

  7. Pharmacodynamic Evaluation

    The ratio of duration(Duration %) with pH ≥ 6 during nocturnal period\* (\*12 hours after administration of investigational product)

    Time frame: Pre-dose(0 hour) up to 12 hours after Investigational product administration in each period

07

Study locations

1 site
  • Seoul National University Hospital, Clinical Trial Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jul 2020, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2020
First posted
Jan 18, 2020
StartActual
Jan 14, 2020
Primary completionActual
Jul 29, 2020
CompletionActual
Aug 3, 2020
Last update
Dec 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04231136
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Jan 14, 2020
Primary completion
Jul 29, 2020
Completion
Aug 3, 2020
Last update
Dec 1, 2020

Study contacts

In-Jin Jang, MD, PhD
principal investigator · Seoul National University Hospital, Dept. of Clinical Pharmacology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion